Zusammenfassung
Grundsätzlich eignen sich alle Proteine mit spezifischer oder überwiegender Expression in Tumorgewebe als Zielstrukturen aktiver bzw. passiver immuntherapeutischer Strategien. Die klinischen Erfolge der letzten Jahre ermutigen die Forschung zur Identifizierung neuer Zielstrukturen. Geeignete Kandidaten sind neben tumoreigenen Proteinen auch solche, die vom Tumorstroma mit hoher Spezifität und Selektivität überexprimiert werden. Dazu gehören z. B. Wachstumsfaktoren, extrazelluläre Matrixproteine und Zelloberflächenproteine neu gebildeter Tumorgefäße. Die Suche nach Kandidatenantigenen erfolgte zunächst mit vorab generierten antitumoralen Antikörpern bzw. T-Zellen, mittlerweile aber überwiegend mit molekularbiologischen und proteinchemischen Hochdurchsatz-Screeningverfahren sowie Datenbankanalysen. Die präklinische Validierung der Kandidatenantigene umfasst neben Untersuchungen zur Verteilung, Homogenität und Stärke ihrer Expression auch die Analyse ihrer funktionellen Bedeutung und – insbesondere für Vakzinierungsstrategien – ihrer tatsächlichen Immunogenität.
Abstract
In principal, all proteins specifically or preferentially expressed in tumor tissues can be regarded as target candidates for active or passive immunotherapy strategies. Clinical success achieved in the past years promotes the identification of new target structures. Aside from proteins expressed by the tumor itself also proteins overexpressed by stromal cells are regarded as suitable candidates. Among the latter are e.g. growth factors, extracellular matrix proteins and cell surface proteins of the tumor neovasculature. The search for candidate target antigens originally depended on the availability of anti-tumor antibodies or T cells, respectively. But in the meantime genomic and proteomic high-throughput screening techniques and data mining procedures clearly dominate. The preclinical validation of candidate antigens includes expression profiling as well as analyses on their functional relevance and – especially for vaccine candidates – their immunogenicity.
Literatur
Rosenberg SA (2004) Shedding light on immunotherapy for cancer. N Engl J Med 350:1461–1463
Carter P, Smith L, Ryan M (2004) Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11:659–687
Rammensee HG, Falk K, Rötzschke O (1993) MHC molecules as peptide receptors. Curr Opin Immunol 5:35–44
Wölfel T, Hauer M, Schneider J et al. (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284
Crotzer VL, Christian RE, Brooks JM et al. (2000) Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol 164:6120–6129
Robbins PF, El-Gamil M, Li YF et al. (1996) A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185–1192
Sharkey MS, Lizee G, Gonzales MI et al. (2004) CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 64:1595–1599
Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799
Parikh AA, Ellis LM (2004) The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 18:951–971
Maecker B, von Bergwelt-Baildon M, Anderson KS et al. (2001) Linking genomics to immunotherapy by reverse immunology--’immunomics‘ in the new millennium. Curr Mol Med 1:609–619
Türeci Ö, Ding J, Hilton H et al. (2003) Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. Faseb J 17:376–385
Flower DR, McSparron H, Blythe MJ et al. (2003) Computational vaccinology: quantitative approaches. Novartis Found Symp 254:102–120; discussion 120–125, 216–222, 250–252
Wikstrand CJ, Hale LP, Batra SK et al. (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140–3148
Skipper JC, Hendrickson RC, Gulden PH et al. (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells resulted from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527–534
Sahin U, Türeci Ö, Pfreundschuh M (1997) Serological identification of human tumor antigens. Curr Opin Oncol 9:709–716
De Plaen E, Lurquin C, Brichard V et al. (1997) Cloning of genes coding for antigens recognized by cytolytic T lymphocytes. Immunology Methods Manual, Academic Press Ltd. 692–718
Kruger T, Schoor O, Lemmel C et al. (2004) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother, Epub ahead of print
Lemmel C, Weik S, Eberle U et al. (2004) Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol 22:450–454
Coulie PG, Ikeda H, Baurein JF, Chiari R (1999) Antitumor immunity at work in a melanoma patient. Adv Cancer Res 76:213–242
Robbins PF, El-Gamil M, Li YF et al. (2002) Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 169:6036–6047
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wölfel, T. Identifizierung von Zielantigenen für Antikörper und T-Zellen. Onkologe 11, 489–493 (2005). https://doi.org/10.1007/s00761-005-0871-z
Issue Date:
DOI: https://doi.org/10.1007/s00761-005-0871-z
Schlüsselwörter
- Spezifische Immuntherapeutika
- T-Zellen
- Antikörper
- Tumorantigene
- Tumorstroma
- Antigenidentifizierung
- Antigenvalidierung